Personalis, Inc. (PSNL)
NASDAQ: PSNL · Real-Time Price · USD
8.16
+0.32 (4.08%)
At close: Mar 9, 2026, 4:00 PM EDT
8.17
+0.01 (0.12%)
After-hours: Mar 9, 2026, 4:07 PM EDT
Personalis Revenue
In the year 2025, Personalis had annual revenue of $69.65M, down -17.69%. Personalis had revenue of $17.35M in the quarter ending December 31, 2025, with 3.24% growth.
Revenue (ttm)
$69.65M
Revenue Growth
-17.69%
P/S Ratio
11.63
Revenue / Employee
$267,877
Employees
260
Market Cap
853.80M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Neogen | 880.32M |
| Myriad Genetics | 824.50M |
| NeoGenomics | 727.33M |
| OPKO Health | 606.88M |
| Veracyte | 517.15M |
| GeneDx Holdings | 427.54M |
| CareDx | 379.81M |
| Castle Biosciences | 344.23M |
PSNL News
- 10 days ago - Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights - Business Wire
- 19 days ago - Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference - Business Wire
- 24 days ago - Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 27 days ago - Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance - Business Wire
- 5 weeks ago - Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors - Business Wire
- 5 weeks ago - Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference - Business Wire
- 7 weeks ago - Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™ - Business Wire